Liquid formulation of long acting insulinotropic peptide conjugate
US9801950B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 25, 2013 |
| Grant date | Oct 31, 2017 |
| Priority date | — |
| Expiry date | Jul 25, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P5/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a liquid formulation of long-acting insulinotropic peptide conjugate, comprising a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.